Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $5.00 Consensus Target Price from Analysts

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has received an average rating of “Hold” from the five ratings firms that are presently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $3.33.

SYRS has been the topic of several recent research reports. Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Piper Sandler reiterated an “overweight” rating and set a $5.00 price objective (down previously from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, HC Wainwright reiterated a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th.

Insider Buying and Selling

In related news, CEO Conley Chee bought 50,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average price of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the transaction, the chief executive officer now directly owns 72,504 shares in the company, valued at $109,481.04. This trade represents a 222.18 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Jason Haas bought 45,344 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were bought at an average cost of $1.68 per share, with a total value of $76,177.92. Following the purchase, the chief financial officer now directly owns 124,552 shares of the company’s stock, valued at approximately $209,247.36. This represents a 57.25 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 130,707 shares of company stock valued at $206,491. 12.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

Several institutional investors have recently bought and sold shares of SYRS. Virtu Financial LLC acquired a new position in shares of Syros Pharmaceuticals during the first quarter valued at approximately $64,000. GSA Capital Partners LLP purchased a new position in Syros Pharmaceuticals in the 3rd quarter worth approximately $34,000. Acadian Asset Management LLC acquired a new position in shares of Syros Pharmaceuticals during the 1st quarter worth approximately $91,000. Certuity LLC purchased a new stake in shares of Syros Pharmaceuticals in the second quarter valued at approximately $109,000. Finally, Kennedy Capital Management LLC acquired a new stake in shares of Syros Pharmaceuticals in the first quarter valued at approximately $2,166,000. 91.47% of the stock is currently owned by institutional investors and hedge funds.

Syros Pharmaceuticals Stock Down 5.7 %

Shares of SYRS stock opened at $0.26 on Wednesday. Syros Pharmaceuticals has a 1-year low of $0.25 and a 1-year high of $8.17. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. The company has a market cap of $6.96 million, a price-to-earnings ratio of -0.09 and a beta of 1.59. The stock’s fifty day moving average price is $1.99 and its 200 day moving average price is $3.74.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter in the previous year, the firm posted ($1.35) earnings per share. On average, research analysts expect that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.